8-K current report · filed Nov 16, 2026

Moderna (MRNA) 8-K Current Report: November 16, 2026

Item 1.01Item 2.03MRNA overview

Short answer

Moderna (MRNA) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). Interest margins reduced 0.75 percentage points, to 4.75% SOFR-based and 3.75% base-rate loans.

Moderna 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Interest margins reduced 0.75 percentage points, to 4.75% SOFR-based and 3.75% base-rate loans
  • Term-loan maturity extended one year, from November 24, 2030 to November 24, 2031
  • Delayed-draw availability extended to November 24, 2029 for $400 million and $500 million commitments
  • Lower borrowing costs and longer access improve Moderna’s financing flexibility, while existing guarantees and collateral remain in place

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 points to Item 1.01 for the terms of Moderna’s new direct financial obligation
  • Investors should review Item 1.01 for obligation amount, maturity, interest rate, and purpose

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Moderna 8-K filings

Get the next MRNA 8-K as it lands

Follow MRNA for push alerts, or ask the research agent what this filing means.